Viridian Therapeutics

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viridian Therapeutics reports strong progress in 2022 with promising trials

Viridian Therapeutics made significant strides in 2022 with positive data on VRDN-001 and plans for Phase 3 trials.
Financially, the company remains strong with $424.6 million in cash, despite increased R&D expenses.
The company's expansion into rare diseases, leadership transition, and strategic clinical site targeting showcase growth potential.
Challenges include dosing frequency impact on efficacy and operational hurdles in patient enrollment and market competition.

Viridian Therapeutics reports strong Q1 performance and strategic advancements

Viridian Therapeutics demonstrated strong performance in clinical trials and financial stability, supported by key hires and strategic partnerships, while facing challenges in investor communication and market access strategies.
The company's focus on innovation in drug delivery methods and pipeline expansion presents opportunities for growth and competitive differentiation in the biopharmaceutical industry.
Overall, Viridian's proactive approach to advancing therapeutic programs and addressing investor concerns positions the company well for future success and potential market impact.

Viridian Therapeutics excels in pipeline progress and financial stability

Viridian Therapeutics showcased strong pipeline progress and financial stability in Q1 2024, with confidence in their transformative therapies.
While facing challenges in regulatory processes and market competition, the company is poised for growth through upcoming program milestones.
Opportunities lie in expanding their therapeutic portfolio, demonstrating product efficacy, and navigating regulatory pathways effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing VRDN-003, an improved subcutaneous version of veligrotug for TED patients, with phase 3 REVEAL-1 and REVEAL-2 topline data expected in early 2026. Promising pipeline candidates include FcRn inhibitors VRDN-006 and bispecific VRDN-008, targeting IgG-mediated autoimmune disorders with potentially superior efficacy.

Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)

Viridian's veligrotug delivered positive data from two phase 3 trials in active and chronic TED patients. The results from the THRIVE-2 trial in chronic TED patients show hints of differentiation to Tepezza with statistically significant effects on diplopia response and diplopia resolution. Veligrotug's results also provide clinical de-risking for next-generation, subcutaneously administered candidate VRDN-003, which I expect to be the key long-term growth driver for the TED franchise.

Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation

Viridian Therapeutics, Inc.'s stock surged over 20% after key trial results came out before the bell on Monday. The study results triggered a rash of buy reissuances from analyst firms and improved the chances of FDA approval for the company's lead candidate in 2026. Even after the rally in VRDN stock on Monday, the stock remains undervalued given its potential market.  The company also has a large cash balance.

Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)

Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the eyes to swell. The post Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease appeared first on Investor's Business Daily.

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

Viridian Therapeutics said on Monday its experimental drug to treat an immune system disorder, chronic thyroid eye disease, met the main goal of a late-stage study.

Viridian Therapeutics' eye disorder drug meets late-stage study goal

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED). TED is an autoimmune condition characterized.

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to host a conference call and webcast to report topline data for the THRIVE-2 phase 3 clinical trial, evaluating veligrotug in chronic TED, on Monday, December 16, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under “Events and.

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 391,500 shares of the company's common stock to 10 new employees (the “Inducem.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.09 per share a year ago.

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the third quarter ending September 30, 2024. “We had another exceedingly strong quarter of execution across our TED and FcRn portfolios,” said Steve Mahoney, Viridian's President and Chief Executive Officer. “In TED, we reporte.

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics, Inc.'s VRDN-001, now Veligrotug, shows promising phase 3 data in Thyroid Eye Disease, outperforming Tepezza in early stages and targeting both active and chronic TED. VRDN-001 achieved significant efficacy in the Thrive trial, meeting all primary and secondary endpoints with strong proptosis and diplopia resolution rates, and was well-tolerated. Financially, Viridian has a market cap of $1.87bn and a cash runway of 9–10 quarters, with a potential annual revenue of $8bn if successful.

Viridian Therapeutics' Superior Prospects Make It A Buy

Aurinia Pharmaceuticals

Corcept Therapeutics

Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the paragraphs below.

3 Small Biotech Stocks With The 'Big Mo' Right Now

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, shares of Series B non-voting convertible preferred stock. Viridian is selling a total of 10,666,600 shares of common stock at a public offering price.

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

The phase III THRIVE study evaluating Viridian's veligrotug for treating active thyroid eye disease meets all primary and secondary endpoints.

VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints

Viridian Therapeutics, Inc. reported that the primary endpoint was met for the phase 3 THRIVE study, using veligrotug for the treatment of patients with active thyroid eye disease. Data release for THRIVE-2 study, using veligrotug for the treatment of patients with chronic thyroid eye disease, expected end of 2024. It is expected that the 7 major thyroid eye disease markets will reach $4.13 billion by 2034.

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock and Series B non-voting convertible preferred stock. All of the securities to be sold in the underwritten public offering are being offered by Viridian. In addition, Viridian inte.

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Viridian Therapeutics Inc (NASDAQ:VRDN) stock is up 11.1% to trade at $15.75 today, and earlier traded as high as $16.35, after the biotech company's eye disorder treatment met the main goal of a late-stage study.

Biotech Stock Scores Big Win, Squeezes Shorts

Viridian Therapeutics stock jumped Tuesday after unveiling promising results for its Amgen-rivaling eye disease treatment.

Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival

Viridian Therapeutics said on Tuesday its experimental drug to treat patients with thyroid eye disease significantly reduced bulging of the eye in a late-stage study.

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from the THRIVE phase 3 clinical trial of VRDN-001, now known as veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). TED is an autoimmune condition chara.

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, will host a conference call and webcast to report topline data for the THRIVE phase 3 clinical trial, evaluating VRDN-001 in patients with active TED, on Tuesday, September 10, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under “Events and Presentat.

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.27 per share a year ago.

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the second quarter ending June 30, 2024. “Our team continues to execute across the board as shown by the progress we have made this quarter, and we are proud to report solid progress in our TED portfolio, with both VRDN-001 pha.

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Catalyst Pharmaceuticals

Verona Pharma

As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks You May Want To Dump This Quarter

Candel Therapeutics

Rocket Pharma

The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should continue to advance. Today, we look in more detail at three small/mid-cap biotech stocks with potential catalysts that should hit before the end of 2024.

News for Viridian Therapeutics Stock (VRDN)